IFRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- InflaRx will present late-breaking preclinical data on izicopan at Kidney Week 2026Oct 2, 2026
- InflaRx reported new mechanistic data supporting izicopan as a potential best-in-class C5aR inhibitorApr 9, 2026
- InflaRx provides update on Phase 3 vilobelimab data analyses in pyoderma gangrenosumDec 30, 2025
- InflaRx reports positive Phase 2a data for INF904 in hidradenitis suppurativa and chronic spontaneous urticariaNov 10, 2025
- InflaRx announces interim analysis results for Phase 3 trial of Vilobelimab in pyoderma gangrenosumMay 28, 2025